Merck’s 11% Drop: A Few Quick Points 2-4-25
Becker Private Equity & Business Podcast - A podcast by Scott Becker
Categorie:
In this episode, Scott Becker breaks down Merck’s 11% stock decline, discussing its strong 2024 performance, concerns over slower growth in 2025, a weak drug pipeline, and upcoming patent expirations.
